Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,53
KB0,68
PKN80,5480,61-2,24
Msft499,42499,470,21
Nokia3,93,95-0,20
IBM256,85257-0,84
Mercedes-Benz Group AG51,7851,80,27
PFE24,4924,5-0,87
10.09.2025 18:59:43
Indexy online
AD Index online
select
AD Index online
 

  • 04.03.2020 11:27:53
Sinopharm Group -H- (Frankfurt)
Závěr k 9.9.2025 Změna (%) Změna (EUR) Objem obchodů (EUR)
2,01 -5,04 -0,14 1 320
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.09.2025
Popis společnosti
Obecné informace
Název společnostiSinopharm Group Co Ltd
Ticker1099
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RIC1099.HK
ISINCNE100000FN7
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.06.2025
Počet zaměstnanců k 30.06.2025 100 251
Akcie v oběhu k 30.06.20253 120 656 191
MěnaCNY
Kontaktní informace
UliceSinopharm Group Building, No. 385, East
MěstoSHANGHAI
PSČ200023
ZeměChina
Kontatní osoba 
Funkce kontaktní osoby 
Telefon862 123 052 666
Fax862123052888

Business Summary: Sinopharm Group Co Ltd is a China-based company principally engaged in the wholesale and retail of pharmaceutical and healthcare products and medical devices. The Company operates its business through four segments. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services to domestic and foreign pharmaceutical and health product manufacturers and other suppliers. The Device Distribution segment distributes medical devices to customers. The Pharmaceutical Retail Business segment owns a network of retail pharmacies that are directly operated or franchised. The Other Business segment is engaged in the manufacture and sale of pharmaceuticals, chemical reagents and laboratory supplies.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Sinopharm Group Co Ltd revenues decreased 3% to RMB286.04B. Net income decreased 6% to RMB3.47B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects G/L on Invest HFS, Maturity & Trading increase of 49% to RMB242.1M (expense), Disposal of portion of equity in assoc decrease from RMB8.4M (income) to RMB0K.
Odvětvová klasifikace
TRBC2012Pharmaceuticals Wholesale
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSMedical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICSPharmacies and Drug Retailers
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICS2007Pharmacies and Drug Stores
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Medical, Dental and Hospital Equipment and Supplies Wholesalers
NAICS1997Pharmacies and Drug Stores
NAICS1997Pharmaceutical Preparation Manufacturing
SICDrugs/proprietaries/sundries
SICMedical And Hospital Equipment
SICDrug Stores/proprietary Stores
SICPharmaceutical Preparations



  • Poslední aktualizace: 10.09.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Executive DirectorWanyong Lian5413.09.202412.01.2018
Chief Financial OfficerXiaojuan Li4801.03.202101.03.2021
Vice PresidentMaisong Cai54
Vice PresidentYang Li4616.11.201816.11.2018
Executive DirectorJinglin Sun4712.02.202512.02.2025
Company SecretaryYijian Wu5429.12.2021